James Gordon CFA
Stock Analyst at Barclays
(3.52)
# 2,261
Out of 5,000 analysts
122
Total ratings
59.4%
Success rate
6.3%
Average return
Main Sectors:
Stocks Rated by James Gordon CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Reiterated: Sell | 1,800p | 1,886p | -4.56% | 30 | Sep 23, 2026 | |
| SWX: GALD Galderma Group AG | Reiterated: Buy | CHF 210.00 → CHF 220.00 | CHF 160.90 | +36.73% | 24 | Sep 8, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Hold | CHF 125.00 → CHF 130.00 | CHF 117.60 | +10.54% | 11 | Sep 8, 2026 | |
| SWX: ROP Roche Holding AG | Reiterated: Buy | CHF 410.00 → CHF 430.00 | CHF 363.20 | +18.39% | 14 | Sep 8, 2026 | |
| SWX: SDZ Sandoz Group AG | Reiterated: Buy | CHF 81.00 → CHF 93.00 | CHF 71.40 | +30.25% | 9 | Sep 8, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Reiterated: Buy | €300.00 | €253.00 | +18.58% | 1 | Sep 8, 2026 | |
| EPA: SAN Sanofi | Reiterated: Hold | €85.00 → €83.00 | €73.11 | +13.53% | 7 | Sep 8, 2026 | |
| LON: HIK Hikma Pharmaceuticals PLC | Upgraded: Hold | 1,350p → 1,700p | 1,595p | +6.58% | 4 | Sep 8, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Reiterated: Sell | €22.00 | €27.62 | -20.35% | 3 | Sep 8, 2026 | |
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 16,500p → 16,000p | 12,430p | +28.72% | 16 | Sep 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $34.75 | - | 1 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $950 | $945.82 | +0.44% | 1 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | kr 530.00 | kr 439.60 | +20.56% | 1 | Jul 3, 2026 |
GSK plc
Sep 23, 2026
Reiterated: Sell
Price Target: 1,800p
Current: 1,886p
Upside: -4.56%
Galderma Group AG
Sep 8, 2026
Reiterated: Buy
Price Target: CHF 210.00 → CHF 220.00
Current: CHF 160.90
Upside: +36.73%
Novartis AG
Sep 8, 2026
Reiterated: Hold
Price Target: CHF 125.00 → CHF 130.00
Current: CHF 117.60
Upside: +10.54%
Roche Holding AG
Sep 8, 2026
Reiterated: Buy
Price Target: CHF 410.00 → CHF 430.00
Current: CHF 363.20
Upside: +18.39%
Sandoz Group AG
Sep 8, 2026
Reiterated: Buy
Price Target: CHF 81.00 → CHF 93.00
Current: CHF 71.40
Upside: +30.25%
Sartorius Aktiengesellschaft
Sep 8, 2026
Reiterated: Buy
Price Target: €300.00
Current: €253.00
Upside: +18.58%
Sanofi
Sep 8, 2026
Reiterated: Hold
Price Target: €85.00 → €83.00
Current: €73.11
Upside: +13.53%
Hikma Pharmaceuticals PLC
Sep 8, 2026
Upgraded: Hold
Price Target: 1,350p → 1,700p
Current: 1,595p
Upside: +6.58%
Lakefront Biotherapeutics NV
Sep 8, 2026
Reiterated: Sell
Price Target: €22.00
Current: €27.62
Upside: -20.35%
AstraZeneca PLC
Sep 7, 2026
Reiterated: Buy
Price Target: 16,500p → 16,000p
Current: 12,430p
Upside: +28.72%
Aug 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $34.75
Upside: -
Jul 24, 2026
Reiterated: Buy
Price Target: $950
Current: $945.82
Upside: +0.44%
Jul 3, 2026
Reiterated: Buy
Price Target: kr 530.00
Current: kr 439.60
Upside: +20.56%